Pre-surgery drug combination for HER2-positive stomach cancer
Part of Cancer, Digestive system clinical trials.
This trial tests two new investigational drugs (SHR-A1811 and SHR-A1701) given before surgery for stomach cancer that is HER2-positive and may respond to immunotherapy. The goal is to see if these drugs can shrink the tumor or improve outcomes when combined with surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with stomach or gastroesophageal junction cancer that is locally advanced (has spread to nearby tissue or lymph nodes) but can still be removed with surgery.
- Your tumor tests positive for HER2 (a protein that can make cancer grow) and also shows at least one of: PD-L1 expression, EBV positivity, or high microsatellite instability (MSI-H).
- You have not had any prior treatment for this cancer, such as chemotherapy, radiation, or immunotherapy.
- You are in generally good health (ECOG score 0 or 1) and are expected to live at least 6 more months.
- You agree to use effective birth control during the study and for 120 days after treatment ends, and you are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of new drugs given before surgery for stomach or gastroesophageal junction cancer. The goal is to see if it can shrink tumors and improve outcomes for patients whose cancer has certain markers.
This trial tests a combination of two targeted drugs, with or without chemotherapy, given before and after surgery for stomach or gastroesophageal junction cancer. It aims to improve the chance of curing the cancer by shrinking it before surgery and controlling any remaining cancer after surgery.
This trial tests a combination of three drugs (targeted therapy, immunotherapy, and chemotherapy) before and after surgery for locally advanced HER2-positive stomach cancer. It aims to see if this treatment can improve outcomes for patients whose cancer has not yet spread.
This trial tests two targeted drugs, trastuzumab deruxtecan and afatinib, together for advanced stomach or gastroesophageal junction cancer that has low levels of the HER2 protein. The goal is to see if the combination shrinks tumors or slows cancer growth.
This study tests a combination of an existing targeted drug (trastuzumab) and a new experimental drug (retlirafusp alfa) for advanced stomach cancer that has a specific marker (HER2) and did not respond to initial treatment. The goal is to see if this combination can help control the cancer.
This trial tests a new drug combined with chemotherapy before surgery for stomach cancer that has spread to nearby areas. It aims to shrink the tumor to make surgery more successful.
Hear when a new Gastric or Gastroesophageal Junction Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.